Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study Journal Article
| Authors: | Lesokhin, A. M.; Ansell, S. M.; Armand, P.; Scott, E. C.; Halwani, A.; Gutierrez, M.; Millenson, M. M.; Cohen, A. D.; Schuster, S. J.; Lebovic, D.; Dhodapkar, M.; Avigan, D.; Chapuy, B.; Ligon, A. H.; Freeman, G. J.; Rodig, S. J.; Cattry, D.; Zhu, L. L.; Grosso, J. F.; Garelik, M. B. B.; Shipp, M. A.; Borrello, I.; Timmerman, J. |
| Article Title: | Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study |
| Abstract: | Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies. Methods In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti-PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression. Results Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks. Conclusion Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B-and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing. (C) 2016 by American Society of Clinical Oncology |
| Keywords: | ipilimumab; response criteria; antibody; expression; multiple-myeloma; b-cell lymphoma; blockade; advanced melanoma; cancer; b7-h1 pd-l1 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 23 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-08-10 |
| Start Page: | 2698 |
| End Page: | 2704 |
| Language: | English |
| ACCESSION: | WOS:000382467000005 |
| DOI: | 10.1200/jco.2015.65.9789 |
| PROVIDER: | wos |
| PMCID: | PMC5019749 |
| PUBMED: | 27269947 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work